Dr Angela Lamarca discusses approaches to first- and second-line therapy for patients with advanced CCA. She touches on current standards of care with combination chemotherapy, and the fact that a change from first-line to second-line therapy is usually done when there is evidence of radiographic progression of disease on first-line therapy. Dr Lamarca looks to the future when the use of molecular profiling may open the door to targeted therapies.
To sign up for our newsletter or print publications, please enter your contact information below.